Next-generation vaccines—eliminating the use of needles

Lead scientist Professor Simon Cutting, from the School of Biological Sciences at Royal Holloway, has developed the jabs through the use of probiotic spores. He carried out fundamental studies into the biology of the bacterium Bacillus subtilis which attracted the attention of microbiologists due to its ability to form spores that can last millions of years before germinating under the appropriate environmental conditions.

Professor Cutting says: "The mechanisms by which this process occurs have fascinated microbiologists for decades making it one of the most intensively studied bacteria. Its simple life cycle and ease of use make it an ideal laboratory subject."

Professor Cutting discovered that the Bacillus spores act as ideal vehicles to carry antigens and promote an immune response. He explains: "Rather than requiring needle delivery, vaccines based on Bacillus spores can be delivered via a , or as on oral liquid or capsule. Alternatively they can be administered via a small soluble film placed under the tongue, in a similar way to modern breath freshners. As spores are exceptionally stable, vaccines based on Bacillus do not require cold-chain storage alleviating a further issue with current vaccine approaches."

As well as eliminating the pain associated with needles, oral vaccines provide greater benefits including being safer to administer, especially in developing countries where HIV is rife, being inexpensive to produce and easier to store and reducing concerns of adverse reactions.

Professor Cutting has carried out pre- of Bacillus-based vaccines for a number of diseases including Tuberculosis, influenza and tetanus but most recently he has been investigating the potential for use of the vaccines against a disease of particular relevance to the West - difficile

"C. difficile, is a gastrointenstinal infection that is commonly picked up following hospital stays and causes around 50,000 infections and 4,000 deaths per year in the UK, mostly in elderly patients. Currently, there is no vaccine against the disease, and although several approaches are currently undergoing clinical trials, none are expected to provide full protection, and new solutions are urgently needed," says Professor Cutting.

He adds: "Bacillus based vaccines offer distinct advantages as unlike other approaches, oral delivery can cause a more specific in the gastrointenstinal tract to fully eliminate C.difficile."

Professor Cutting has recently received private seed investment to form a company, Holloway Immunology, to develop the bacillus vaccine technology and concentrate on three lead vaccines for Tuberculosis, C. difficile infection and influenza (flu). The company is currently looking for investors to help fast track the implementation of these jabs and contribute to the transformation of vaccine delivery around the globe.

Related Stories

Better vaccines for tuberculosis could save millions of lives

Aug 28, 2012

Cases of one of the world's deadliest diseases—tuberculosis—are rising at an alarming rate, despite widespread vaccination. Reasons for the ineffectiveness of the vaccine, especially in regions where this infectious disease ...

New low-cost method to deliver vaccine shows promise

Nov 16, 2010

Researchers have developed a promising new approach to vaccination for rotavirus, a common cause of severe diarrheal disease that is responsible for approximately 500,000 deaths among children in the developing ...

Recommended for you

High-dose opioid prescribing continues to climb

Sep 12, 2014

High-dose opioid prescribing increased by 23 per cent in Canada between 2006 and 2011, despite clinical guidelines recommending that most patients should avoid high-doses of these drugs, according to new ...

Feds say Bayer colon supplement makes bogus claims

Sep 12, 2014

The United States government accused Bayer of making scientifically unproven statements about the health benefits of a popular probiotic on Friday, claiming the German pharmaceutical giant was in contempt of court.

FDA approves weight-loss drug Contrave (Update)

Sep 11, 2014

U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation's 78 million obese adults.

User comments